LAG3 and cancer: In contrast to cancer cells, the transfection efficiencies of T cells are likely to be more consistent between patients and may be seen as prime target for nucleic acid immune checkpoint blockade as they express multiple regulatory molecules, for example, T-cell immunoglobulin mucin-3 (TIM-3) and lymphocyte activation gene 3 (LAG-3) [91,92].